{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:19:51Z","timestamp":1793841591252,"version":"4.6.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":203,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.beem.2023.101773","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T11:48:28Z","timestamp":1678362508000},"page":"101773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Chemokines in thyroid autoimmunity"],"prefix":"10.1016","volume":"37","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Rosaria","family":"Paparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Patrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ghionzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Varricchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Ulisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2023.101773_bib1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20021897","article-title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4","volume":"197","author":"Lasagni","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.beem.2023.101773_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2008.04.022","article-title":"Chemokines and neuromodulation","volume":"198","author":"M\u00e9lik\u2013Parsadaniantz","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.beem.2023.101773_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/eje.1.02137","article-title":"Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process","volume":"154","author":"Antonelli","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2023.101773_bib5","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2002-12-3945","article-title":"CXCR3- mediated chemotaxis of human T cells is regulated by a Giand phospholipase C-dependent pathway and not via activation of MEK\/p44\/p42 MAPK nor Akt\/PI-3 kinase","volume":"102","author":"Smit","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beem.2023.101773_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beem.2023.101773_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-2008-1073153","article-title":"Chemokines and autoimmune thyroid diseases","volume":"40","author":"Liu","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2023.101773_bib8","doi-asserted-by":"crossref","first-page":"dgz289","DOI":"10.1210\/clinem\/dgz289","article-title":"Th1 chemokines in autoimmune endocrine disorders","volume":"105","author":"Fallahi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2023.101773_bib10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cyto.2011.04.022","article-title":"Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10","volume":"55","author":"Antonelli","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.beem.2023.101773_bib11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1210\/jc.2010-2905","article-title":"Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis","volume":"96","author":"Antonelli","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cyto.2010.01.009","article-title":"Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"50","author":"Antonelli","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.beem.2023.101773_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.autrev.2016.09.009","article-title":"The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients","volume":"15","author":"Fallahi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2023.101773_bib14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/thy.2010.0103","article-title":"Urticaria and thyroid autoimmunity","volume":"21","author":"Bagnasco","year":"2011","journal-title":"Thyroid J Am Thyroid Assoc"},{"key":"10.1016\/j.beem.2023.101773_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750380","article-title":"Precision medicine in autoimmune thyroiditis and hypothyroidism","volume":"12","author":"Ferrari","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.beem.2023.101773_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.2006.02447.x","article-title":"Increase of interferongamma- inducible CXC chemokine CXCL10 serum levels in patients with active Graves\u2019 disease, and modulation by methimazole therapy","volume":"64","author":"Antonelli","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.autrev.2018.10.001","article-title":"The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2023.101773_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.metabol.2010.02.002","article-title":"Cytokines (interferon-\u03b3 and tumor necrosis factor-\u03b1)-induced nuclear factor-\u03baB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone","volume":"60","author":"Antonelli","year":"2011","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.beem.2023.101773_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2014.01.006","article-title":"CXCR3, CXCL10 and type 1 diabetes","volume":"25","author":"Antonelli","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.beem.2023.101773_bib20","first-page":"e181","article-title":"Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine","volume":"165","author":"Corrado","year":"2014","journal-title":"La Clin Ter"},{"key":"10.1016\/j.beem.2023.101773_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","article-title":"CXCR3, inflammation, and autoimmune diseases","volume":"1173","author":"Lacotte","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.beem.2023.101773_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.autrev.2012.10.001","article-title":"The interaction between CXCL10 and cytokines in chronic inflammatory arthritis","volume":"12","author":"Lee","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2023.101773_bib23","first-page":"1809","article-title":"Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis","volume":"35","author":"Antonelli","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.beem.2023.101773_bib24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/08916930802170401","article-title":"High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis","volume":"41","author":"Antonelli","year":"2008","journal-title":"Autoimmunity"},{"key":"10.1016\/j.beem.2023.101773_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1465-9921-14-121","article-title":"Interferon-inducible chemokines reflect severity and progression in sarcoidosis","volume":"14","author":"Su","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.beem.2023.101773_bib26","first-page":"e305","article-title":"HCV-related autoimmune disorders in HCV chronic infection","volume":"164","author":"Ferrari","year":"2013","journal-title":"La Clin Ter"},{"key":"10.1016\/j.beem.2023.101773_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/468107","article-title":"Cytokines and HCV-related disorders","volume":"2012","author":"Fallahi","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.beem.2023.101773_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/1744666X.2015.997214","article-title":"Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection","volume":"11","author":"Zignego","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.beem.2023.101773_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v7.i3.327","article-title":"Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin\u2019s lymphoma, and cancer","volume":"7","author":"Ferri","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.beem.2023.101773_bib30","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1677\/ERC-08-0337","article-title":"Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptorgamma agonists","volume":"16","author":"Antonelli","year":"2009","journal-title":"Endocr-Relat Cancer"},{"key":"10.1016\/j.beem.2023.101773_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1398-9995.1998.tb04951.x","article-title":"The Th1\/Th2 paradigm and allergic disorders","volume":"53","author":"Romagnani","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.beem.2023.101773_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves' disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.beem.2023.101773_bib34","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/j.lpm.2012.10.002","article-title":"Thyroid autoimmunity","volume":"41","author":"Orgiazzi","year":"2012","journal-title":"Presse Med"},{"key":"10.1016\/j.beem.2023.101773_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12020-012-9703-2","article-title":"The incidence and prevalence of thyroid autoimmunity","volume":"42","author":"McLeod","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2023.101773_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2265.2008.03338.x","article-title":"The incidence of autoimmune thyroid disease: a systematic review of the literature","volume":"69","author":"McGrogan","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101367","article-title":"Hashimotos' thyroiditis: epidemiology, pathogenesis, clinic and therapy","volume":"33","author":"Ragusa","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.semcancer.2019.05.019","article-title":"Thyroid autoimmune disorders and cancer","volume":"64","author":"Ferrari","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.beem.2023.101773_bib39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1210\/er.2002-0030","article-title":"Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function","volume":"24","author":"Tomer","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2023.101773_bib40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2265.2011.04318.x","article-title":"Twin studies as a model for exploring the aetiology of autoimmune thyroid disease","volume":"76","author":"Brix","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib41","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1210\/jc.2011-1568","article-title":"Innate immune activation and thyroid autoimmunity","volume":"96","author":"Kawashima","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib42","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.autrev.2016.01.001","article-title":"Smoke and autoimmunity: the fire behind the disease","volume":"15","author":"Perricone","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2023.101773_bib43","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1210\/jc.2006-1571","article-title":"Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter","volume":"92","author":"Antonelli","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cen.12066","article-title":"Selenium and the thyroid gland: more good news for clinicians","volume":"78","author":"Drutel","year":"2013","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib45","first-page":"36","article-title":"Myo-inositol and selenium reduce the risk of developing overt hypothyroidism in patients with autoimmune thyroiditis","volume":"21","author":"Ferrari","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.beem.2023.101773_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves' disease: epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib47","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1210\/jcem.86.10.7953","article-title":"Thyrocytes from autoimmune thyroid disorders produce the chemokines IP\u201310 and Mig and attract CXCR3+ lymphocytes","volume":"86","author":"Garc\u00eda\u2013L\u00f3pez","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cyto.2019.01.003","article-title":"Immunological aspects of autoimmune thyroid disease - Complex interplay between cells and cytokines","volume":"116","author":"Luty","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.beem.2023.101773_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2265.2004.02085.x","article-title":"Cellular immune responses in autoimmune thyroid disease","volume":"61","author":"Weetman","year":"2004","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib50","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1210\/jc.2004-0977","article-title":"High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism","volume":"89","author":"Antonelli","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1530\/eje.1.01847","article-title":"Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis","volume":"152","author":"Antonelli","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib52","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-2008-1073151","article-title":"Circulating chemokines in patients with autoimmune thyroid diseases","volume":"40","author":"Domberg","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2023.101773_bib53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/09513590.2013.871514","article-title":"Higher levels of circulating CXCL-9 and CXCL-11 in euthyroid women with autoimmune thyroiditis and recurrent spontaneous abortions","volume":"30","author":"Aktas","year":"2014","journal-title":"Gynecol Endocrinol: J Int Soc Gynecol Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib54","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1530\/EC-18-0019","article-title":"Aberrant MRP14 expression in thyroid follicular cells mediates chemokine secretion through the IL-1\u03b2\/MAPK pathway in Hashimoto\u2019s thyroiditis","volume":"7","author":"Luo","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2023.101773_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.770852","article-title":"Immunological microenvironment alterations in follicles of patients with autoimmune thyroiditis","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beem.2023.101773_bib56","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.autrev.2010.08.018","article-title":"Bioassays for TSH-receptor autoantibodies: an update","volume":"10","author":"Lytton","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2023.101773_bib57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cei.12129","article-title":"A novel bioassay for anti- thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity","volume":"173","author":"Li","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.beem.2023.101773_bib58","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1055\/a-0723-9023","article-title":"Thyrotropin receptor blocking antibodies","volume":"50","author":"Diana","year":"2018","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2023.101773_bib59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12980","article-title":"Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease","volume":"189","author":"Diana","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.beem.2023.101773_bib60","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective trial of functional thyrotropin receptor antibodies in Graves disease","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.754386","article-title":"Precision medicine in Graves' disease and ophthalmopathy","volume":"12","author":"Elia","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.beem.2023.101773_bib62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.2006.02447.x","article-title":"Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy","volume":"64","author":"Antonelli","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/thy.2009.0179","article-title":"Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves' disease in long-term remission","volume":"20","author":"Sakai","year":"2010","journal-title":"Thyroid J Am Thyroid Assoc"},{"key":"10.1016\/j.beem.2023.101773_bib64","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0019","volume":"156","author":"Inukai","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1677\/JOE-07-0240","article-title":"Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes","volume":"195","author":"Crescioli","year":"2007","journal-title":"J Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib66","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0031-1271620","article-title":"Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease","volume":"43","author":"Leite","year":"2011","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2023.101773_bib67","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1210\/jc.2005-1689","article-title":"Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"91","author":"Antonelli","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib68","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1210\/jc.2008-2450","article-title":"Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"94","author":"Antonelli","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib69","doi-asserted-by":"crossref","first-page":"E413","DOI":"10.1210\/jc.2010-0923","article-title":"CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes","volume":"95","author":"Antonelli","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib71","unstructured":"Davies T.F., Burch H.B. Clinical features and diagnosis of Graves\u2019 orbitopathy (ophthalmopathy) (2019). Available at: \u3008https:\/\/www.uptodate.com\/contents\/pathogenesis-of-graves-disease\/\u3009 (Accessed on March 03, 2023)."},{"key":"10.1016\/j.beem.2023.101773_bib72","doi-asserted-by":"crossref","first-page":"7453260","DOI":"10.1155\/2019\/7453260","article-title":"Immunological aspects of Graves' ophthalmopathy","volume":"2019","author":"\u0141acheta","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.beem.2023.101773_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/en.2005-1018","article-title":"T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy","volume":"147","author":"Han","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2023.101773_bib74","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.4049\/jimmunol.175.2.1310","article-title":"IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy","volume":"175","author":"Chen","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.beem.2023.101773_bib75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5603\/EP.2014.0021","article-title":"The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD)","volume":"65","author":"Miko\u015b","year":"2014","journal-title":"Endokrynol Pol"},{"key":"10.1016\/j.beem.2023.101773_bib76","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib77","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaophthalmol.2018.0806","article-title":"Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy","volume":"136","author":"Rotondo Dottore","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.beem.2023.101773_bib78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2011.11.001","article-title":"Peroxisome proliferator-activated receptor-\u03b1 agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes","volume":"349","author":"Antonelli","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib79","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2014.08.025","article-title":"Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete \u03b1 (CXCL10) and \u03b2 (CCL2) chemokines under the influence of cytokines that are modulated by PPAR\u03b3","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2023.101773_bib80","doi-asserted-by":"crossref","first-page":"bqac203","DOI":"10.1210\/endocr\/bqac203","article-title":"Macrophage-orbital fibroblast interaction and hypoxia promote inflammation and adipogenesis in Graves' orbitopathy","volume":"164","author":"G\u00f6rtz","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2023.101773_bib81","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/thy.1997.7.579","article-title":"Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy","volume":"7","author":"Baschieri","year":"1997","journal-title":"Thyroid: J Am Thyroid Assoc"},{"key":"10.1016\/j.beem.2023.101773_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.654473","article-title":"Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy","volume":"12","author":"Fallahi","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib83","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101773_bib84","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","article-title":"Management of graves thyroidal and extrathyroidal disease: an update","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib85","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101773_bib86","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2023.101773_bib87","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.beem.2023.101773_bib88","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1089\/thy.2015.0518","article-title":"Primary cell culture systems for human thyroid studies","volume":"26","author":"Wang","year":"2016","journal-title":"Thyroid J Am Thyroid Assoc"},{"key":"10.1016\/j.beem.2023.101773_bib89","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.semcancer.2020.06.013","article-title":"Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin","volume":"79","author":"Fallahi","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.beem.2023.101773_bib90","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2007.03.113","article-title":"Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice","volume":"133","author":"Lee","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2023.101773_bib91","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/424163","article-title":"Combined treatment with myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis","volume":"2013","author":"Nordio","year":"2013","journal-title":"J Thyroid Res"},{"key":"10.1016\/j.beem.2023.101773_bib92","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11154-018-9477-9","article-title":"Myo-inositol in autoimmune thyroiditis, and hypothyroidism","volume":"19","author":"Fallahi","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2023.101773_bib93","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s12020-014-0477-6","article-title":"Selenium: an element for life","volume":"48","author":"Duntas","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2023.101773_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101377","article-title":"Endocrine disruptors and thyroid autoimmunity","volume":"34","author":"Benvenga","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101773_bib95","doi-asserted-by":"crossref","first-page":"a018788","DOI":"10.1101\/cshperspect.a018788","article-title":"Signaling in lymphocyte activation","volume":"7","author":"Cantrell","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.beem.2023.101773_bib96","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40618-016-0535-4","article-title":"Influence of short-term selenium supplementation on the natural course of Hashimoto's thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial","volume":"40","author":"Esposito","year":"2017","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.beem.2023.101773_bib97","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.endinu.2019.03.018","article-title":"Selenium supplementation in patients with subclinical hypothyroidism affected by autoimmune thyroiditis: Results of the SETI study","volume":"67","author":"Pirola","year":"2020","journal-title":"Endocrinol, Diabetes Y Nutr"},{"key":"10.1016\/j.beem.2023.101773_bib98","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.3390\/nu14142869","article-title":"Assessment of the effect of selenium supplementation on production of selected cytokines in women with Hashimoto's thyroiditis","volume":"14","author":"Kryczyk-Kozio\u0142","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.beem.2023.101773_bib99","first-page":"89","article-title":"Favorable effects of myo-inositol, selenomethionine or their combination on the hydrogen peroxide-induced oxidative stress of peripheral mononuclear cells from patients with hashimoto\u2019s thyroiditis: preliminary in vitro studies","volume":"2","author":"Benvenga","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.beem.2023.101773_bib100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11154-018-9476-x","article-title":"The protective effect of myo-inositol on human thyrocytes","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:59:47Z","timestamp":1761497987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X23000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521690X23000441"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2023.101773","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemokines in thyroid autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2023.101773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101773"}}